How I treat patients with polycythemia vera

Blood

Volumn 109, Issue 12, 2007, Pages 5104-5111

  Finazzi, Guido ^a   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; DESMOPRESSIN; HYDROXYUREA; IMATINIB; PAROXETINE; PSORALEN; TRANEXAMIC ACID;

BLEEDING; CARDIOTOXICITY; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; GASTROINTESTINAL TOXICITY; HAIR LOSS; HUMAN; INCIDENCE; LEUKOCYTOSIS; MORBIDITY; MORTALITY; MUSCLE WEAKNESS; MYALGIA; PHLEBOTOMUS; POLYCYTHEMIA VERA; PREDICTION; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; WEIGHT REDUCTION;

EID: 34249983486     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-12-038968     Document Type: Review

References (76)

1. Tefferi A, Barbui T. bcr/abl negative, classic myeloproliferative disorders: diagnosis and treatment. Mayo Clin Proc. 2005;80:1220-1232.
2. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452-2466.
3. Prchal JF, Axelrad AA. Bone marrow responses in polycythemia vera. N Engl J Med. 1974;290:1382.
4. Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006;107:4214-4222.
5. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144-1148.
6. Levine RL, Wadleigh M, Cools J, et al. Activating mutation of the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
7. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet. 2005;365:1054-1061.
8. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
9. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788-22792.
10. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617 mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168.
11. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23:132-143.
12. Pierre R, Vardiman JW, Imbert M, Brunning RD, Thiele J, Flandrin G. Polycythemia vera. In: Jaffe ES, Harris NL, Stein H, Vardiman JE, eds. WHO Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:32-34.
13. Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand. 1962;172:513-523.
14. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224-2232.
15. Barbui T, Finazzi G. Evidence-based management of polycythemia vera. Best Pract Res Clin Haematol. 2006;19:483-493.
16. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2004;128:275-290.
17. Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005;129:553-560.
18. Patel RK, Lea N, Heneghan A, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130:2031-2038.
19. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528-1534.
20. Chung RT, Iafrate AJ, Amrein PC, Sahani DV, Misdraji J. Case 15-2006: a 46-year-old woman with sudden onset of abdominal distention. N Engl J Med. 2006;354:2166-2175.
21. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556-562.
22. Di Nisio M, Barbui T, Di Gennaro L, et al. The hematocrit and platelet target in polycythemia vera. Br J Haematol. 2006;136:249-259.
23. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. Prepublished on November 14, 2006, as DOI 10.1182/blood-2006-08-042515.
24. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81:159-166.
25. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and JAK2 mutation status. Blood. Prepublished on November 16, 2006, as DOI 10.1182/blood-2006-09-046342.
26. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523-530.
27. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes C. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91:169-175.
28. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130:174-195.
29. V617F mutational load at diagnosis on major clinical aspects in patients with polycythemia vera. Blood. 2006;108:6a. Abstract 5.
30. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978;2:1219-1222.
31. Tartaglia AP, Goldberg JD, Berk PD, et al. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol. 1986;23:172-176.
32. Streiff MB, Smith B, Spivak JL. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of the American Society of Hematology members' practice patterns. Blood. 2002;99:1144-1149.
33. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287-1294.
34. Gruppo Italiano Studio Policitemia. Low-dose aspirin in polycythemia vera: a pilot study. Br J Haematol. 1997;97:453-456.
35. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
36. Fruchtman SM, Mack K, Kaplan ME, Pterson P, Berk PD, Wasserman LR. From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34:17-23.
37. Najean Y, Rain JD for the French Polycythemia Study Group. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370-3377.
38. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. N Engl J Med. 1995;332:1132-1136.
39. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33-45.
40. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000;110:577-583.
41. Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythemia. Drugs. 2006;66:111-131.
42. 2 production of polymorphonuclear neutrophils fronm patients with sickle cell anemia. Blood. 2002;99:2297-2303.
43. Halsey C, Roberts IAG. The role of hydroxyurea in sickle cell disease. Br J Haematol. 2003;120:177-186.
44. Guillot B, Bessis D, Dereure O. Mucocutaneous side effects of antineoplastixc chemotherapy. Expert Opin Drug Saf. 2004;3:579-587.
45. Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am J Hematol. 1996;52:42-46.
46. Sterkers Y, Preudhomme C, Lai J-L, et al. Acute myeloid leukemia and myelodyslastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91:616-622.
47. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol. 1997;34:29-39.
48. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood. 2003;101:3749.
49. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1,638 patients enrolled in a prospective observational study. Blood. 2005;105:2664-2670.
50. De Montalembert M, Brousse V, Elie C, Bernaudin F, Shi J, Landais P. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica. 2006;91:125-128.
51. Silver RT. Interferon alpha2b: a new treatment for polycythemia vera. Ann Intern Med. 1993;119:1091-1092.
52. Martyre MC. Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. Curr Hematol Rep. 2003;2:257-263.
53. Lengfelder E, Berger U, Hehlmann R. Interferon alpha in the treatment of polycythemia vera. Ann Hematol. 2000;79:103-109.
54. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-lpha. Cancer. 2006;107:451-458.
55. Quintas-Cardama A, Kantarjian HM, Giles F, Verstovsek S. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost. 2006;32:409-416.
56. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108:2037-2040.
57. Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or with interferon alpha. Blood. 2006;107:3339-3341.
58. Samuelsson J, Mutschler M, Birgegard G, Gram-Hansen P, Bjorkholm M, Pahl HL. Limited effects on JAK2 mutational status after pegylated interferon α-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica. 2006;91:1281-1282.
59. Silver RT. Imatinib mesylate (Gleevec) reduces phlebotomy requirements in polycythemia vera. Leukemia. 2003;17:1186-1187.
60. Pardanani A, Hood J, Lasho T, et al. TG101209, a selective JAK2 kinase inhibitor, suppressess endogenous and cytokine-supported colony formation from hematopoietic progenitors carrying JAK2V617F or MPLW515K/L mutations. Blood. 2006;108:758a. Abstract 2680.
61. Gaikwad AS, Prchal JT. Efficacy of tyrosine kinase inhibitors in polycythemia vera. Blood. 2006;108:762a. Abstract 2696.
62. Hood J, Cao J, Hanna E, et al. JAK2 inhibitors for the treatment of myeloproliferative disorders. Blood. 2006;108:1038a. Abstract 3632.
63. Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost. 1997;23:425-431.
64. Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol. 2006;19:617-633.
65. Hirsh J, Guyatt G, Albers GW, Schunemann HJ. The seventh ACCP conference on antithrombotic and thrombolytic therapy: evidence-based guidelines. Chest. 2004;126:172S-173S.
66. Condat B, Pessione F, Hillaire S, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 2001;120:490-497.
67. Narayanan Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med. 2004;350:578-585.
68. Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, vanVliet HHDM. Platelet-mediated thrombotic complications in patients with ET: reversal by aspirin, platelet reduction and not by coumadin. Blood Cells Mol Dis. 2006;36:199-205.
69. De Stefano V, Za T, Rossi T, et al. Recurrent thrombosis in patients with polycythemia vera or essential thrombocythemia: efficacy of treatment in preventing rethrombosis in different clincal settings. Blood. 2006;108:39a. Abstract 119.
70. Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood. 2002;99:2627.
71. Jeanmougin M, Rain JD, Najean Y. Efficacy of photochemotherapy on severe pruritus in polycythemia vera. Ann Hematol. 1996;73:91-93.
72. Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol. 2005;129:293-306.
73. Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/ polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Haemost. 2006;32:422-429.
74. Barbui T, Finazzi G. Myeloproliferative disease in pregnancy and other management issues. Hematology Am Soc Hematol Educ Program. 2006;246-252.
75. Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN. The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica. 2005;90:1477-1483.
76. Ruggeri M, Rodeghiero F, Tosetto A, et al. Thrombotic and hemorrhagic complications after surgery in patients with essential thrombocythemia and polycythemia vera. Blood. 2006;108:761a. Abstract 2693.